impact so on always lives the is patients have the hear It NUPLAZID their Steve. to and of can caregivers. gratifying you, Thank
and continue demonstrated indications, of new safety by approved we was a activities. to remains based clinical benefits number robust and has our of NUPLAZID efficacy, focus with clinically in data the Phase of along pimavanserin pivotal been study X supportive treatment statistically on front other center that primary As from always FDA evaluate and a the the as potential highly significant studies.
risk in behind stand the the continuously benefits XXXX, in this completed are safety for of on totality long-term is both We profile ongoing trials. assessment has studies NUPLAZID it available studies, information, base first, clinical in period described positive NUPLAZID's unchanged and safety following: of new ongoing the and firmly we remains or evaluations efficacy launch Based open-label throughout this this confident the treatment on robust risks placebo-controlled our placebo-controlled approval the of in Since, product and in We approval no risk and NUPLAZID’s evaluating We're and revealed benefit monitored maintain after safety ACADIA that also appropriately the labeling. and in and information. NUPLAZID activities. profile currently pharmacovigilance it. changed our pimavanserin
common reported pimavanserin the of that not put patients. studies rates of to reassuring reviews conclusion mechanism The the NUPLAZID. of remain the identify clinical Psychosis clinical when we and Alzheimer's patient's third, difference XXX of the in and elderly literature an NUPLAZID etiology of no placebo; and age, context between reported with advanced analysis and in any to safety and safety or of In pathophysiological insurance deaths presence NUPLAZID comparable would and other there and a patients of postmarketing events causal observed comorbidities; disease, aggregate in data frail data PD our large underlying studies mortality in and sets second, was consistent are deaths conditions signal-detection addition, relationship serious morbidity did with medical the postmarketing number in lead fatal controlled from the database approximately adverse
relationship as Event an around for postmarketing reports NUPLAZID known NUPLAZID and database drug FDA a correctly System, the or Adverse the reflected to extrapolated Report FAERS of is media indicator or recent having profile in The data safety causal reported a any alone not information is short. event FDA, the which adverse Some biologic. of FAERS, between
while patient occur events not on does As does biologic, or the that to not or particular caused exposure the information database or contain drug the drug drug particular adverse FAERS any the adverse this explains mean database a a the that on its about on biologic website, collection FAERS adverse FDA events underlying Further, while is contains reports methodology. event. a
comparisons is inferences make between products understand, draw possible or alone. this appropriate based on information it So not to reliable
associated with considered and For direct reported for specialty is contact instance, are with NUPLAZID there interaction from that if of coming is caregivers. channel, distributed therefore which we XX% consider are better through a direct solicited. patients are events a NUPLAZID and through adverse Approximately reported frequent and distribution understood this NUPLAZID number
originating distributed products of On and spontaneous event patients caregivers consumers higher the results approximately almost Increased significantly with reports through spontaneous. rely NUPLAZID X% of care other and adverse in other voluntary retail considered only way. hand, most to drugs prompted channel, this therefore entirely In are event are are and from interaction compared which or professionals reporting. contrast, adverse health on reports number a not reports distributed
adequately FDA to a identified reports. indicated described a of appropriate compare to stated on based also issue raw recent the safety draw In it safety or not had it information. number they already a based conclusions in response on to-date, emerging the product label. of performing the specific that As not reports, simply FDA not that were is an is result, evaluation otherwise media that The information
while response all We their safety to that remind have like what benefit does respond mean part the that information FDA should that conducted. not to suffering press has from psychosis. suggesting or the evaluation FDA debilitating new and in the should the FDA concluded as is not to you taking the patients drugs stop has taking continue will inquiries, of process. Parkinson's the stop has that additional a track of medication agency NUPLAZID their also of To that drug the is being risk disease repeat drug prescribing symptoms I stated patients already providers to evaluation requests offers from for issue the and to this the would facilitate evaluation healthcare to
X patients response. Our improvement of psychosis XX% approximately study showed some and experienced XX% pivotal complete on show Phase
impact Additionally, symptoms. negative motor on patient's show overall no
for a We're programs development options. indications potential treatment new strong on CNS either are pimavanserin. updates or to there advancing need turn there approved in treatments late-stage four areas, no now where for Let's is
update may these As each provide pimavanserin brief serotonin approach agonist, a treating to selective I a will on of a conditions. inverse provide now new studies. these debilitating
We psychosis dementia-related first persistent suggest commonly sites psychosis, and enrollment. have in our few to have consisting FDA-approved have patients study with both psychosis, of dementia for condition there this that HARMONY that initiated to associated X study make solid currently initial dementia-related psychosis has dementia and been with off-label the severe opening approximately enrollment in been serious XX% cognition months respect continued or Serious psychosis are to fourth treatment. XXXX the Phase study impair by with Studies no impaired used which for related global hallucinations and First, translated in in treat quarter in population. consequences medical progress is interest of the patients of numbers the delusions. with this to trial. medications excellent and patient a dementia of Tremendous already shown investigator in
very forward to on you with look and are plan much continued this our on updating study progress. We
of to According medications, hallucinations patients to to XX% American they inadequate but about Second, with exhibit continue response. improvement, schizophrenia that response antipsychotic or have Psychiatric residual have delusions. schizophrenia meaning inadequate Association,
make continue and with progress out this to next read results We study year. expect to
approved prominent of treat symptoms, Third, functioning. limited patients schizophrenia-negative of remain treatments for symptoms. is Studies to functionally because suffer social show XX% negative XX% target drug symptoms. currently schizophrenia. impaired, patients available positive that cognitive of schizophrenia no from to negative symptoms, Because symptoms about and There currently deficit antipsychotic most schizophrenia
majority a to antidepressant of fourth, make for depressive progress respond to of initial We readout from leading XX study this disability therapy. MDD disorder. And year. people next do not is who XX. continue major MDD suffer with ages cause results to The and expect
of earlier, this As our our in performance. to from stated Steve now discuss plan I MDD Michael to Phase II second will half commercial turn announce in the we to results year. top-line study the call
